Status:
UNKNOWN
The Development of a Metabolomic Test to Diagnose and Quantify Pancreatic Exocrine Insufficiency (The DETECTION Study)
Lead Sponsor:
University Hospital Birmingham NHS Foundation Trust
Collaborating Sponsors:
Pancreatic Cancer UK
Conditions:
Pancreatic Exocrine Insufficiency
Eligibility:
All Genders
16+ years
Phase:
NA
Brief Summary
DETECTION. The development of a metabolomic test to diagnose and quantify pancreatic exocrine insufficiency.
Detailed Description
Pancreatic exocrine insufficiency (PEI) is prevalent and progressive among patients with pancreatic cancer, treatment with pancreatic enzyme replacement therapy (PERT) has been proven to reduce gastro...
Eligibility Criteria
Inclusion
- Inclusion Criteria: (for main pancreatic cancer cohort)
- PDAC
- PEI (as defined by breath test)
- Tolerating oral diet Inclusion Criteria: (for CF cohort)
- CF
- PEI (as defined by breath test)
- Tolerating oral diet Inclusion Criteria: (for CP cohort)
- CP
- PEI (as defined by breath test)
- Tolerating oral diet
- Exclusion Criteria (all arms):
- No other GI conditions
- For each arm no evidence of the other arm conditions
- For health controls, no history of CP, CF or pancreatic cancer
- No GI surgery (except pancreatic resection in the pancreatic cancer cohort)
- Unable to consent
- Unable to travel to UHB for testing
- Prognosis \< 2months
- Performance status 2+
Exclusion
Key Trial Info
Start Date :
August 24 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2024
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT05980221
Start Date
August 24 2020
End Date
October 1 2024
Last Update
August 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospitals Birmingham NHS Foundation Trust
Birmingham, United Kingdom